Comparative Pharmacology
Head-to-head clinical analysis: ANGIOVIST 292 versus GADAVIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIOVIST 292 versus GADAVIST.
ANGIOVIST 292 vs GADAVIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiovist 292 (diatrizoate meglumine and diatrizoate sodium) is an ionic, high-osmolar iodinated contrast agent. It functions by absorbing x-rays due to the high atomic number of iodine, thereby enhancing the radiopacity of vascular structures and organs during diagnostic imaging. It also increases the osmolarity of the intravascular compartment, which can lead to hemodynamic effects.
Gadovist (gadobutrol) is a macrocyclic gadolinium-based contrast agent (GBCA) that enhances MRI signal intensity by shortening T1 relaxation time in tissues with altered vascularity or blood-brain barrier integrity.
Intravenous administration: 50-150 mL of a 292 mg iodine/mL solution for adults, depending on the imaging procedure, with a maximum total dose of 300 mL per procedure.
0.1 mmol/kg (0.2 mL/kg) IV bolus; maximum dose 0.3 mmol/kg per imaging session.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; prolonged to >30 hours in severe renal impairment (CrCl <30 mL/min).
Plasma terminal elimination half-life is approximately 1.5 hours in patients with normal renal function (GFR >60 mL/min/1.73m²). In renal impairment (GFR <30 mL/min/1.73m²), half-life extends to 10-15 hours; in end-stage renal disease, half-life may exceed 30 hours, necessitating adjustment of imaging timing.
Primarily renal; >90% of dose excreted unchanged in urine within 24 hours. Fecal excretion is negligible (<1%).
Primarily renal; approximately 95% of administered dose excreted unchanged in urine within 72 hours, with 85% eliminated within 6 hours. Less than 1% excreted in feces.
Category C
Category C
Contrast Agent
Contrast Agent